The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

20VC: Inside Carnegie Mellon's $4BN Endowment | Why 90% of LPs Shouldn't Invest in VC | The $140BN Problem with Multi-Stage Funds | The Hidden Math Behind DPI, TVPI, and Illiquidity with Miles Dieffenbach

203 snips
Aug 4, 2025
Miles Dieffenbach, the Managing Director of Investments at Carnegie Mellon University, oversees a $4 billion endowment. He shares how surviving cancer reshaped his perspective on resilience and investment decisions. The discussion dives into why 90% of limited partners might not benefit from venture capital, the pitfalls of seed funds, and the significant issues multi-stage funds face. He also addresses the evolving dynamics of founder-friendly approaches and the critical role that brand plays in LP decisions.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
00:00 / 00:00

Cancer Shaped Miles' Perspective

  • Miles Dieffenbach shares how his cancer diagnosis at 26 changed his mindset radically.
  • He focused on how he reacted, pushing through with strength until becoming cancer-free in four months.
00:00 / 00:00

CMU Endowment Portfolio Composition

  • Carnegie Mellon Endowment allocates 85% equity and 15% fixed income, with 50% in private assets.
  • The endowment's private equity book is self-funding in the last three years despite venture being a detractor in distributions.
00:00 / 00:00

Venture Returns Often Don’t Match Risks

  • Most LPs are not compensated enough for the risk they take in venture capital.
  • Top decile managers deliver returns above public market equivalent, but many LPs lack access to such managers.
Get the Snipd Podcast app to discover more snips from this episode
Get the app